{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:08:43Z","timestamp":1788782923425,"version":"build-2803163510"},"reference-count":37,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP170638"],"award-info":[{"award-number":["RP170638"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007914","name":"University of Texas Southwestern Medical Center","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100007914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nectin-4\u2013targeted imaging has emerged as a promising strategy for patient stratification in urothelial carcinoma, yet currently available radiotracers remain limited by rapid renal clearance, urinary background activity, or potential pharmacologic confounding associated with antibody-drug conjugate (ADC)-based constructs. To overcome some of these limitations, we developed a payload-free immunoPET radiotracer based on the native enfortumab antibody conjugated with the bifunctional chelator DFO*-sq and radiolabeled with zirconium-89 (89Zr). The resulting [89Zr]Zr-DFO*-sq-Enfortumab preserved Nectin-4\u2013specific targeting while demonstrating high radiochemical stability in human serum (&amp;gt;99% through Day 12). In vitro studies showed efficient antigen-specific cellular internalization (80\u201385%), prolonged intracellular retention, and evidence consistent with partial recycling of antibody-associated species. In vivo, [89Zr]Zr-DFO*-sq-Enfortumab exhibited sustained tumor uptake reaching 17.4 \u00b1 2.8% ID\/g in high Nectin-4\u2013expressing xenografts and correlated with differential Nectin-4 expression across multiple bladder cancer models. Importantly, the full-length antibody platform enabled high-contrast visualization of pulmonary metastatic lesions and orthotopic bladder tumors despite some urinary background activity. Together, these findings demonstrate that payload-free [89Zr]Zr-DFO*-sq-Enfortumab provides a biologically relevant immunoPET platform for noninvasive assessment of variable Nectin-4 expression and support its further evaluation as a companion imaging strategy for Enfortumab Vedotin\u2013based therapies.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00746","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:02:36Z","timestamp":1786460556000},"page":"4758-4769","source":"Crossref","is-referenced-by-count":0,"title":["Payload-Free\n[89Zr]Zr-DFO*-sq-Enfortumab\nImmunoPET for Imaging Nectin-4 Expression in Bladder Cancer"],"prefix":"10.1021","volume":"23","author":[{"given":"Marian N.","family":"Aziz","sequence":"first","affiliation":[{"name":"The University of Texas Southwestern Medical Center , , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern Medical Center , , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Lang","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern Medical Center , , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickey","family":"Glover","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern Medical Center , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhilash","family":"Boppana","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern Medical Center , , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sashi","family":"Debnath","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern Medical Center , , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui Wan","family":"Loh","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern Medical Center , , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeon","family":"Lee","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern Medical Center , , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Yan","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern Medical Center , , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at Houston , , , ,","place":["Houston, Texas, United States, 77030"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5140-6110","authenticated-orcid":true,"given":"Xiankai","family":"Sun","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern Medical Center , , , ,","place":["Dallas, Texas, United States, 75390"]},{"name":"The University of Texas Southwestern Medical Center , , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jer-Tsong","family":"Hsieh","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern Medical Center , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern Medical Center , , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern Medical Center , , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyang","family":"Hao","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern Medical Center , , , ,","place":["Dallas, Texas, United States, 75390"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"2026090707080159300_cit1","doi-asserted-by":"publisher","first-page":"1354543","DOI":"10.3389\/fonc.2024.1354543","article-title":"Therapeutic\nprospects of nectin-4 in cancer: applications and value","volume":"14","author":"Li","year":"2024","journal-title":"Front. Oncol"},{"key":"2026090707080159300_cit2","doi-asserted-by":"publisher","first-page":"217681","DOI":"10.1016\/j.canlet.2025.217681","article-title":"Nectin-4 expression\npatterns and therapeutics in oncology","volume":"622","author":"Nikanjam","year":"2025","journal-title":"Cancer\nLett"},{"key":"2026090707080159300_cit3","unstructured":"US FDA grants approval and expands indication for\nPADCEV (enfortumab\nvedotin-ejfv) for patients with locally advanced or metastatic urothelial\ncancer. Seagen Inc. and Astellas Pharma Inc.https:\/\/bit.ly\/3r7jzJ2 Accessed\n9 July 2021."},{"key":"2026090707080159300_cit4","unstructured":"FDA grants regular approval\nto enfortumab vedotin-ejfv for locally\nadvanced or metastatic urothelial cancer. FDAhttps:\/\/bit.ly\/3xxXlSC Accessed 9 July 2021."},{"issue":"4","key":"2026090707080159300_cit5","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA Approval\nSummary: Enfortumab Vedotin for Locally\nAdvanced or Metastatic Urothelial Carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin. Cancer Res"},{"key":"2026090707080159300_cit6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.euros.2023.04.018","article-title":"Enfortumab\nVedotin in Metastatic Urothelial Carcinoma:\nSurvival and Safety in a European Multicenter Real-world Patient Cohort","volume":"53","author":"Zschabitz","year":"2023","journal-title":"Eur. Urol. Open Sci"},{"issue":"10","key":"2026090707080159300_cit7","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: A Phase I Study\nof Single-Agent Enfortumab\nVedotin in Patients With Nectin-4-Positive Solid Tumors, Including\nMetastatic Urothelial Carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J. Clin. Oncol"},{"issue":"12","key":"2026090707080159300_cit8","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial\nCarcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"18","key":"2026090707080159300_cit9","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4\nExpression Across Molecular Subtypes of Urothelial Cancer Mediates\nSensitivity to Enfortumab Vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin. Cancer\nRes"},{"issue":"2","key":"2026090707080159300_cit10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bju.16643","article-title":"Spatial\ndistribution and subtype-specific expression\npatterns of Nectin-4 in muscle-invasive bladder cancer","volume":"136","author":"Olah","year":"2025","journal-title":"BJU Int"},{"issue":"17","key":"2026090707080159300_cit11","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","article-title":"First-in-Human\nStudy of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET\/CT Imaging\nof Advanced Urothelial Carcinoma","volume":"29","author":"Duan","year":"2023","journal-title":"Clin. Cancer\nRes"},{"issue":"Supplement\n1","key":"2026090707080159300_cit12","doi-asserted-by":"publisher","first-page":"12S","DOI":"10.2967\/jnumed.123.266830","article-title":"Translational PET Imaging of Nectin-4 Expression in\nMultiple Different Cancers with 68Ga-N188","volume":"65","author":"Zhang","year":"2024","journal-title":"J.\nNucl. Med"},{"key":"2026090707080159300_cit13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/bju.16901","article-title":"Staging metastatic urothelial\ncancer with Nectin-4 imaging using Gallium-68-N188 PET\/CT","volume":"137","author":"Miederer","year":"2026","journal-title":"BJU Int"},{"issue":"3","key":"2026090707080159300_cit14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2967\/jnumed.124.269024","article-title":"Pilot\nStudy of Nectin-4\u2013Targeted PET Imaging Agent 68Ga-FZ-NR-1 in\nTriple-Negative Breast Cancer from Bench to First-in-Human","volume":"66","author":"Sun","year":"2025","journal-title":"J. Nucl. Med"},{"key":"2026090707080159300_cit15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00259-025-07402-z","article-title":"Rapid and specific immunoPET imaging of Nectin-4 in\ngastric cancer\nand non-small cell lung cancer using [64Cu]Cu-NOTA-EV-F(ab\u2019)2","volume":"53","author":"Huang","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"20","key":"2026090707080159300_cit16","doi-asserted-by":"publisher","first-page":"21366","DOI":"10.1021\/acs.jmedchem.5c01260","article-title":"A Radiofluorinated\nNanobody PET Tracer\nto Dynamically Visualize Differential Nectin4 Expression In Vivo","volume":"68","author":"Zheng","year":"2025","journal-title":"J. Med. Chem"},{"issue":"6","key":"2026090707080159300_cit17","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1021\/acs.molpharmaceut.5c00469","article-title":"ImmunoPET Imaging of Nectin4 Expression\nin Gastric and Bladder Cancer Using [64Cu]Cu-NOTA-Padcev","volume":"22","author":"Huang","year":"2025","journal-title":"Mol. Pharmaceutics"},{"key":"2026090707080159300_cit18","doi-asserted-by":"publisher","first-page":"123756","DOI":"10.1016\/j.ijpharm.2023.123756","article-title":"An iodine-labelled\nAntibody\u2013drug conjugate PET probe for noninvasive monitoring\nof Nectin-4 expression in urothelial carcinoma","volume":"651","author":"Ren","year":"2024","journal-title":"Int. J. Pharm"},{"key":"2026090707080159300_cit19","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ccell.2026.04.010","article-title":"Endocytic evasion confers resistance to antibody-drug\nconjugates therapy in cancer","volume":"44","author":"Wang","year":"2026","journal-title":"Cancer Cell"},{"issue":"80","key":"2026090707080159300_cit20","doi-asserted-by":"publisher","first-page":"11889","DOI":"10.1039\/C6CC05961A","article-title":"A desferrioxamine\nB squaramide ester for the incorporation of zirconium-89 into antibodies","volume":"52","author":"Rudd","year":"2016","journal-title":"Chem. Commun"},{"issue":"3","key":"2026090707080159300_cit21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s00259-020-05002-7","article-title":"Head-to-head\ncomparison\nof DFO* and DFO chelators: selection of the best candidate for clinical\n89Zr-immuno-PET","volume":"48","author":"Chomet","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"8","key":"2026090707080159300_cit22","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/ijc.22405","article-title":"The use\nof histone deacetylase inhibitor FK228 and DNA hypomethylation agent\n5-azacytidine in human bladder cancer therapy","volume":"120","author":"Karam","year":"2007","journal-title":"Int. J. Cancer"},{"issue":"22","key":"2026090707080159300_cit23","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1158\/1078-0432.CCR-22-1547","article-title":"ImmunoPET\nImaging with 89Zr-Labeled Atezolizumab\nEnables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal\nCell Carcinoma","volume":"28","author":"Mulgaonkar","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"2026090707080159300_cit24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12894-022-01093-6","article-title":"Establishment\nof an optimized orthotopic bladder cancer model in\nmice","volume":"22","author":"Cai","year":"2022","journal-title":"BMC Urol"},{"issue":"1","key":"2026090707080159300_cit25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","article-title":"Determination\nof the immunoreactive function of radiolabeled monoclonal antibodies\nby linear extrapolation to binding at infinite antigen excess","volume":"72","author":"Lindmo","year":"1984","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"2026090707080159300_cit26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s40425-019-0607-z","article-title":"PD-L1 detection using 89Zr-atezolizumab immuno-PET\nin renal cell carcinoma tumorgrafts from a patient with favorable\nnivolumab response","volume":"7","author":"Vento","year":"2019","journal-title":"J. Immunother Cancer"},{"issue":"10","key":"2026090707080159300_cit27","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.2967\/jnumed.110.075648","article-title":"ImmunoSPECT and ImmunoPET of IGF-1R\nExpression with the Radiolabeled Antibody R1507 in a Triple-Negative\nBreast Cancer Model","volume":"51","author":"Heskamp","year":"2010","journal-title":"J. Nucl. Med"},{"issue":"3","key":"2026090707080159300_cit28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder\nCancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"8","key":"2026090707080159300_cit29","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous\nNECTIN-4 Expression Frequently Decreases\nduring Metastatic Spread of Urothelial Carcinoma and Is Associated\nwith Enfortumab Vedotin Resistance","volume":"29","author":"Klumper","year":"2023","journal-title":"Clin. Cancer\nRes"},{"issue":"8","key":"2026090707080159300_cit30","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1158\/1078-0432.CCR-22-3882","article-title":"Scratching\nthe Surface: NECTIN-4\nas a Surrogate for Enfortumab Vedotin Resistance","volume":"29","author":"Aggen","year":"2023","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"2026090707080159300_cit31","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ady1111","article-title":"Nectin-4 PET\nfor predicting enfortumab vedotin dose-response in urothelial carcinoma","volume":"12","author":"Mishra","year":"2026","journal-title":"Sci. Adv"},{"issue":"9","key":"2026090707080159300_cit32","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1007\/s00259-019-04343-2","article-title":"Direct comparison of the in vitro and in vivo stability\nof DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET","volume":"46","author":"Raave","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"2026090707080159300_cit33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.22038\/AOJNMB.2022.68093.1471","article-title":"Development and evaluation of (89)Zr-trastuzumab\nfor clinical applications","volume":"11","author":"Mohammadpour-Ghazi","year":"2023","journal-title":"Asia Ocean J. Nucl.\nMed. Biol"},{"issue":"1","key":"2026090707080159300_cit34","doi-asserted-by":"publisher","first-page":"1976705","DOI":"10.1080\/19420862.2021.1976705","article-title":"Selective\ndepletion of radiolabeled HER2-specific antibody for contrast improvement\nduring PET","volume":"13","author":"Khare","year":"2021","journal-title":"MAbs"},{"issue":"7","key":"2026090707080159300_cit35","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.2967\/jnumed.113.136481","article-title":"Use of Fc-Engineered Antibodies as Clearing Agents\nto Increase Contrast During PET","volume":"55","author":"Swiercz","year":"2014","journal-title":"J. Nucl. Med"},{"issue":"12","key":"2026090707080159300_cit36","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.7150\/thno.84865","article-title":"Click-to-Release:\nCleavable Radioimmunoimaging with [(89)Zr]Zr-DFO-Trans-Cyclooctene-Trastuzumab\nIncreases Tumor-to-Blood Ratio","volume":"13","author":"Vlastara","year":"2023","journal-title":"Theranostics"},{"key":"2026090707080159300_cit37","doi-asserted-by":"publisher","first-page":"1360710","DOI":"10.3389\/fnume.2024.1360710","article-title":"Advances and\nchallenges in immunoPET\nmethodology","volume":"4","author":"Mohr","year":"2024","journal-title":"Front Nucl. Med"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00746","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/9\/4758\/66492949\/acs.molpharmaceut.6c00746.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/9\/4758\/66492949\/acs.molpharmaceut.6c00746.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:21:37Z","timestamp":1788780097000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/9\/4758\/5252444\/Payload-Free-89Zr-Zr-DFO-sq-Enfortumab-ImmunoPET"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,11]]},"published-print":{"date-parts":[[2026,9,7]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00746","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]}}}